Uniphar Stock

Uniphar EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Uniphar (UPR.IR) as of Aug 6, 2026 is 91.43 M EUR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 85.12 M EUR — a change of 7.41% (higher).

EBITDA

91.43 MEUR

YoY

7.41%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Uniphar is 2026 91.43 M EUR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Uniphar was 2025 85.12 M EUR. It decreases by 7.41% higher compared to the previous year.
Access this data via the Eulerpool API

Uniphar Stock analysis

What does Uniphar do? Uniphar PLC is an Irish company that was founded in 1994 and operates in the healthcare industry. The company is headquartered in Dublin and employs over 2,500 people worldwide. The history of Uniphar began as a pharmacy distribution company that supplied medications to retailers and healthcare facilities. Over the years, however, the company has expanded its business model and now offers a wide range of healthcare products and services. Uniphar's business model encompasses three main areas: Healthcare Services, Commercial & Clinical Supply Chain, and Product Access & Specialty Medicines. In the Healthcare Services area, Uniphar provides consulting services, training, and leadership coaching for healthcare facilities. The Commercial & Clinical Supply Chain division includes the storage, logistics, and distribution of medications, as well as the clinical care of patients. The Product Access & Specialty Medicines division focuses on access to medications with high medical demand and rare diseases. Uniphar also offers a wide range of healthcare products, including generics, branded medications, and medical devices. The company has partnerships with leading pharmaceutical companies such as Pfizer, Eli Lilly, and Merck. In recent years, Uniphar has also made several significant acquisitions to expand and diversify its business. In 2018, the company acquired UK-based pharmaceutical distributor Cahill May Roberts, and in 2019, the acquisition of Durbin, an international supplier of clinical supply products, was completed. Uniphar is committed to improving healthcare in Ireland and worldwide and offers a wide range of products and services to achieve this goal. The company has earned a reputation as a reliable partner for healthcare facilities and pharmaceutical companies and is on a steady growth trajectory. Uniphar is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Uniphar stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Uniphar is 91.43 M EUR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Uniphar changed from 85.12 M EUR to 91.43 M EUR, representing a 7.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Uniphar since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Uniphar historically and in real time.

Access this data via the Eulerpool API

Income Statement — Uniphar

All Key Metrics — Uniphar